Mr. Riad Mishlawi, CEO of Hybio Pharmaceutical's Global Partner Hikma, Visits with His Executive Team to Deepen Long-Term Cooperation
From April 10-11, 2025, Mr. Riad Mishlawi, CEO of the renowned global pharmaceutical company Hikma, led an executive team to visit Hybio Pharmaceutical. The two parties conducted a systematic evaluation of their strategic cooperation achievements in recent years and engaged in in-depth discussions on future cooperation directions. The goal of this visit was to further strengthen the partnership and provide more high-quality pharmaceutical solutions to patients worldwide.
The Hikma delegation included core management members: CEO Mr. Riad Mishlawi, Executive Vice President Mr. Bassam Kanaan, Vice Presidents Mr. Faisal Darwazeh and Mr. Kareem Darwazeh, and China Regional Head Mr. Knight Zhou. They were warmly received by senior leaders from Hybio Pharmaceutical, including Chairman and President Mr. Zeng Shaogui, Director and Executive President Ms. Yu Pinxiang, and Vice President Mr. Zhang Baole, who participated in the full exchange.
Since establishing a strategic partnership in 2019, the two companies have achieved significant results based on complementary strengths. Notably, Hikma's key product this year, Liraglutide Injection, was successfully approved by the U.S. Food and Drug Administration (FDA) in 2024, becoming the first generic version to be marketed in the U.S.. This milestone marks a major breakthrough in their commercial cooperation. The synergy between them was fully demonstrated by leveraging Hikma's mature distribution network and brand influence in the North American market and Hybio Pharmaceutical's core competencies in registration and declaration, quality control, and large-scale production. Both parties agreed that there is still huge potential for future cooperation in a wider range of market areas.
During the visit, the Hikma delegation specifically toured Hybio Pharmaceutical's formulation manufacturing base in Pingshan. This base has been strictly built in accordance with European and American cGmp (Good Manufacturing Practice) standards since it was put into operation in 2013 and successfully passed an FDA on-site inspection in 2023. The delegation conducted an on-site inspection of key production lines, including the vial production line, cartridge production line, and automatic pen assembly line, as well as the quality control laboratory equipped with internationally advanced testing equipment. They observed the complete production process from raw material dispensing to online quality monitoring. The Hikma team highly praised the Hybio Pharmaceutical team's efficient execution and strict quality control system, believing it provides a solid guarantee for the quick response capability of their cooperative products in the U.S. market.
During the subsequent symposium, the two parties had an in-depth exchange on the performance of their collaborative drugs in the North American market. Hikma provided a detailed presentation on the market layout of liraglutide injection across traditional hospitals, chain pharmacies, and e-commerce platforms. It also analyzed the current status of the FDA's drug shortage list and specifically explained the joint measures taken by both parties regarding supply assurance and production Process Optimization.
Hybio Pharmaceutical shared its development plan for its upcoming pipeline of peptide and small nucleic acid formulations. The Hikma delegation expressed great interest and approval, looking forward to replicating the successful model of liraglutide cooperation to more therapeutic areas and different regions globally to maximize economies of scale and jointly provide better pharmaceutical products and services to patients worldwide.
About Hikma
Hikma Pharmaceuticals (stock code: LSE:HIK, listed on the London Stock Exchange on November 4, 2005) was founded in 1978 and is headquartered in London, UK. In 2024, its global revenue exceeded $3 billion, making it one of the top ten global multinational generic drug companies. Its business covers more than 50 countries, including the U.S., the Middle East and North Africa (MENA), and Europe, with over 800 product varieties. The therapeutic categories of drugs it develops include anti-infectives, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory diseases.
About Hybio Pharmaceutical
Hybio Pharmaceutical (stock code: 300199, listed on the Shenzhen Stock Exchange on April 7, 2011) was founded in 2003 and has always focused on the fields of Peptide Drugs and small nucleic acids. Its products and businesses cover innovative peptide drugs, high-barrier generic peptide drugs, peptide and small nucleic acid APIs, and CDMO. The company has established a vertically integrated upstream, midstream, and downstream industry chain, ensuring full-chain control from raw materials to drugs.